Biological therapies in the systemic management of psoriasis: International Consensus Conference

被引：142

作者：

Sterry, W

Barker, J

Boehncke, WH

Bos, JD

Chimenti, S

Christophers, E

de la Brassinne, M

Ferrandiz, C

Griffiths, C

Katsambas, A

Kragballe, K

Lynde, C

Menter, A

Ortonne, JP

Papp, K

Prinz, J

Rzany, B

Ronnevig, J

Saurat, JH

Stahle, M

Stengel, FM

van de Kerkhof, P

Voorhees, J

机构：

[1] Univ Hosp Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany

[2] St Thomas Hosp, St Johns Inst Dermatol, London, England

[3] Goethe Univ Frankfurt, D-6000 Frankfurt, Germany

[4] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[5] Univ Roma Tor Vergata, Dermatol Clin, Rome, Italy

[6] Univ Kiel, Kiel, Germany

[7] Univ Hosp Liege, Liege, Belgium

[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[9] Univ Manchester, Manchester, Lancs, England

[10] Univ Athens, Sch Med, GR-11527 Athens, Greece

[11] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[12] Lynde Ctr Dermatol, Toronto, ON, Canada

[13] Texas Dermatol Res Inst, Dallas, TX USA

[14] Univ Nice, Nice, France

[15] Univ Western Ontario, London, ON, Canada

[16] Univ Munich, Munich, Germany

[17] Univ Oslo, Natl Hosp, Dept Dermatol, Oslo, Norway

[18] Hop Cantonal Univ Geneva, Geneva, Switzerland

[19] Karolinska Univ Hosp, Stockholm, Sweden

[20] Univ Inst Cem Dermatol, Buenos Aires, DF, Argentina

[21] Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands

[22] Univ Michigan, Sch Med, Ann Arbor, MI USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2004年 / 151卷

关键词：

alefacept; biologicals; efalizumab; etanercept; infliximab; psoriasis;

D O I：

10.1111/j.1365-2133.2004.06070.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Psoriasis is a chronic, immune-mediated disorder that usually requires long-term treatment for control. Approximately 25% of patients have moderate to severe disease and require phototherapy, systemic therapy or both. Despite the availability of numerous therapeutic options, the long-term management of psoriasis can be complicated by treatment-related limitations. With advances in molecular research and technology, several biological therapies are in various stages of development and approval for psoriasis. Biological therapies are designed to modulate key steps in the pathogenesis of psoriasis. Collectively, biologicals have been evaluated in thousands of patients with psoriasis and have demonstrated significant benefit with favourable safety and tolerability profiles. The limitations of current psoriasis therapies, the value of biological therapies for psoriasis, and guidance regarding the incorporation of biological therapies into clinical practice are discussed.

引用

页码：3 / 17

页数：15

共 107 条

[1] Therapeutic strategies for psoriasis [J].